Hyperinsulinemia fails to augment ET-1 action in the skeletal muscle vascular bed in vivo in humans

Amale A. Lteif, Angie D. Fulford, Robert V. Considine, Inessa Gelfand, Alain D. Baron, Kieren J. Mather

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Endogenous endothelin action is augmented in human obesity and type 2 diabetes and contributes to endothelial dysfunction and impairs insulin-mediated vasodilation in humans. We hypothesized that insulin resistance-associated hyperinsulinemia could preferentially drive endothelin-mediated vasoconstriction. We applied hyperinsulinemic-euglycemic clamps with higher insulin dosing in obese subjects than lean subjects (30 vs. 10 mU·m -2·min-1, respectively), with the goal of matching insulin's nitric oxide (NO)-mediated vascular effects. We predicted that, under these circumstances, insulin-stimulated endothelin-1 (ET-1) action (assessed with the type A endothelin receptor antagonist BQ-123) would be augmented in proportion to hyperinsulinemia. NO bioactivity was assessed using the nitric oxide synthase inhibitor NG-monomethyl-L-arginine. Insulin-mediated vasodilation and insulin-stimulated NO bioavailability were well matched across groups by this approach. As expected, steady-state insulin levels were approximately threefold higher in obese than lean subjects (109.2 ± 10.2 pmol/l vs. 518.4 ± 84.0, P = 0.03). Despite this, the augmentation of insulin-mediated vasodilation by BQ-123 was not different between groups. ET-1 flux across the leg was not augmented by insulin alone but was increased with the addition of BQ-123 to insulin (P = 0.01 BQ-123 effect, P = not significant comparing groups). Endothelin antagonism augmented insulin-stimulated NO bioavailability and NOx flux, but not differently between groups and not proportional to hyperinsulinemia. These findings do not support the hypothesis that insulin resistance-associated hyperinsulinemia preferentially drives endothelin-mediated vasoconstriction.

Original languageEnglish (US)
Pages (from-to)E1510-E1517
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume295
Issue number6
DOIs
StatePublished - Dec 1 2008

Fingerprint

Hyperinsulinism
Endothelin-1
Blood Vessels
Skeletal Muscle
Insulin
Endothelins
Nitric Oxide
Vasodilation
Vasoconstriction
Biological Availability
Insulin Resistance
omega-N-Methylarginine
Glucose Clamp Technique
Nitric Oxide Synthase
Type 2 Diabetes Mellitus
Leg
Research Design
Obesity
cyclo(Trp-Asp-Pro-Val-Leu)

Keywords

  • Endothelin-1
  • Insulin
  • Obesity

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Endocrinology, Diabetes and Metabolism

Cite this

Hyperinsulinemia fails to augment ET-1 action in the skeletal muscle vascular bed in vivo in humans. / Lteif, Amale A.; Fulford, Angie D.; Considine, Robert V.; Gelfand, Inessa; Baron, Alain D.; Mather, Kieren J.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 295, No. 6, 01.12.2008, p. E1510-E1517.

Research output: Contribution to journalArticle

@article{c4fe5f004cf84435aee9a11dbf92b511,
title = "Hyperinsulinemia fails to augment ET-1 action in the skeletal muscle vascular bed in vivo in humans",
abstract = "Endogenous endothelin action is augmented in human obesity and type 2 diabetes and contributes to endothelial dysfunction and impairs insulin-mediated vasodilation in humans. We hypothesized that insulin resistance-associated hyperinsulinemia could preferentially drive endothelin-mediated vasoconstriction. We applied hyperinsulinemic-euglycemic clamps with higher insulin dosing in obese subjects than lean subjects (30 vs. 10 mU·m -2·min-1, respectively), with the goal of matching insulin's nitric oxide (NO)-mediated vascular effects. We predicted that, under these circumstances, insulin-stimulated endothelin-1 (ET-1) action (assessed with the type A endothelin receptor antagonist BQ-123) would be augmented in proportion to hyperinsulinemia. NO bioactivity was assessed using the nitric oxide synthase inhibitor NG-monomethyl-L-arginine. Insulin-mediated vasodilation and insulin-stimulated NO bioavailability were well matched across groups by this approach. As expected, steady-state insulin levels were approximately threefold higher in obese than lean subjects (109.2 ± 10.2 pmol/l vs. 518.4 ± 84.0, P = 0.03). Despite this, the augmentation of insulin-mediated vasodilation by BQ-123 was not different between groups. ET-1 flux across the leg was not augmented by insulin alone but was increased with the addition of BQ-123 to insulin (P = 0.01 BQ-123 effect, P = not significant comparing groups). Endothelin antagonism augmented insulin-stimulated NO bioavailability and NOx flux, but not differently between groups and not proportional to hyperinsulinemia. These findings do not support the hypothesis that insulin resistance-associated hyperinsulinemia preferentially drives endothelin-mediated vasoconstriction.",
keywords = "Endothelin-1, Insulin, Obesity",
author = "Lteif, {Amale A.} and Fulford, {Angie D.} and Considine, {Robert V.} and Inessa Gelfand and Baron, {Alain D.} and Mather, {Kieren J.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1152/ajpendo.90549.2008",
language = "English (US)",
volume = "295",
pages = "E1510--E1517",
journal = "American Journal of Physiology",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "6",

}

TY - JOUR

T1 - Hyperinsulinemia fails to augment ET-1 action in the skeletal muscle vascular bed in vivo in humans

AU - Lteif, Amale A.

AU - Fulford, Angie D.

AU - Considine, Robert V.

AU - Gelfand, Inessa

AU - Baron, Alain D.

AU - Mather, Kieren J.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Endogenous endothelin action is augmented in human obesity and type 2 diabetes and contributes to endothelial dysfunction and impairs insulin-mediated vasodilation in humans. We hypothesized that insulin resistance-associated hyperinsulinemia could preferentially drive endothelin-mediated vasoconstriction. We applied hyperinsulinemic-euglycemic clamps with higher insulin dosing in obese subjects than lean subjects (30 vs. 10 mU·m -2·min-1, respectively), with the goal of matching insulin's nitric oxide (NO)-mediated vascular effects. We predicted that, under these circumstances, insulin-stimulated endothelin-1 (ET-1) action (assessed with the type A endothelin receptor antagonist BQ-123) would be augmented in proportion to hyperinsulinemia. NO bioactivity was assessed using the nitric oxide synthase inhibitor NG-monomethyl-L-arginine. Insulin-mediated vasodilation and insulin-stimulated NO bioavailability were well matched across groups by this approach. As expected, steady-state insulin levels were approximately threefold higher in obese than lean subjects (109.2 ± 10.2 pmol/l vs. 518.4 ± 84.0, P = 0.03). Despite this, the augmentation of insulin-mediated vasodilation by BQ-123 was not different between groups. ET-1 flux across the leg was not augmented by insulin alone but was increased with the addition of BQ-123 to insulin (P = 0.01 BQ-123 effect, P = not significant comparing groups). Endothelin antagonism augmented insulin-stimulated NO bioavailability and NOx flux, but not differently between groups and not proportional to hyperinsulinemia. These findings do not support the hypothesis that insulin resistance-associated hyperinsulinemia preferentially drives endothelin-mediated vasoconstriction.

AB - Endogenous endothelin action is augmented in human obesity and type 2 diabetes and contributes to endothelial dysfunction and impairs insulin-mediated vasodilation in humans. We hypothesized that insulin resistance-associated hyperinsulinemia could preferentially drive endothelin-mediated vasoconstriction. We applied hyperinsulinemic-euglycemic clamps with higher insulin dosing in obese subjects than lean subjects (30 vs. 10 mU·m -2·min-1, respectively), with the goal of matching insulin's nitric oxide (NO)-mediated vascular effects. We predicted that, under these circumstances, insulin-stimulated endothelin-1 (ET-1) action (assessed with the type A endothelin receptor antagonist BQ-123) would be augmented in proportion to hyperinsulinemia. NO bioactivity was assessed using the nitric oxide synthase inhibitor NG-monomethyl-L-arginine. Insulin-mediated vasodilation and insulin-stimulated NO bioavailability were well matched across groups by this approach. As expected, steady-state insulin levels were approximately threefold higher in obese than lean subjects (109.2 ± 10.2 pmol/l vs. 518.4 ± 84.0, P = 0.03). Despite this, the augmentation of insulin-mediated vasodilation by BQ-123 was not different between groups. ET-1 flux across the leg was not augmented by insulin alone but was increased with the addition of BQ-123 to insulin (P = 0.01 BQ-123 effect, P = not significant comparing groups). Endothelin antagonism augmented insulin-stimulated NO bioavailability and NOx flux, but not differently between groups and not proportional to hyperinsulinemia. These findings do not support the hypothesis that insulin resistance-associated hyperinsulinemia preferentially drives endothelin-mediated vasoconstriction.

KW - Endothelin-1

KW - Insulin

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=57349157849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57349157849&partnerID=8YFLogxK

U2 - 10.1152/ajpendo.90549.2008

DO - 10.1152/ajpendo.90549.2008

M3 - Article

C2 - 18957616

AN - SCOPUS:57349157849

VL - 295

SP - E1510-E1517

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0193-1849

IS - 6

ER -